Astria Therapeutics is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORECAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND)...Read more
CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation...Read more
NEW YORK, March 27, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that the US Food and Drug Administration (FDA) has accepted Delcath Systems, Inc.'s (Delcath) new...Read more
Data presented at plenary session of Society of Gynecologic Oncology Meeting Patients treated suffered from platinum resistant/refractory ovarian cancer Previous PD-(L)1/CTLA-4 combinations have reported only 3-10% responses in comparable patient populations1,2 Findings...Read more
WILMINGTON, Del. / Mar 27, 2023 / Business Wire / Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were...Read more
Eplontersen met co-primary endpoints demonstrating sustained reduction in TTR and benefits in neuropathy and quality of life through 66 weeks 35 and 66-week data to be presented at the American Academy of Neurology (AAN) Annual Meeting in April CARLSBAD, Calif., March 27, 2023...Read more
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Mettler-Toledo | 9.36 0.64 | $1,469.11 |
| Elevance Health | 7.06 1.55 | $463.75 |
| Repligen | 6.72 4.19 | $166.98 |
| Novartis | 6.12 7.32 | $89.71 |
| Reata Pharmaceuticals | 5.31 6.20 | $91.01 |
| Bio-Rad Laboratories | 5.20 1.13 | $465.98 |
| Humana | 5.02 1.00 | $507.45 |
| Thermo Fisher Scientific | 4.56 0.82 | $562.82 |
| CONMED | 4.18 4.31 | $101.18 |
| Teleflex | 4.00 1.61 | $252.94 |
| UnitedHealth | 3.98 0.84 | $479.97 |
| ResMed | 3.24 1.52 | $215.83 |
| Chemed | 3.23 0.62 | $526.00 |
| Catalent | 3.07 4.78 | $67.34 |
| BeiGene | 2.66 1.21 | $222.37 |
| DexCom | 2.65 2.32 | $116.74 |
| Madrigal Pharmaceuticals | 2.51 1.07 | $237.18 |
| Company | Volume | Last Trade |
|---|---|---|
| Signify Health | 28,326,293 | $30.48 |
| Pyxis Oncology | 23,933,505 | $2.79 |
| Coeptis Therapeutics | 9,312,236 | $1.65 |
| Gamida Cell | 6,107,119 | $0.96 |
| Jounce Therapeutics | 5,586,789 | $1.85 |
| Cyclerion Therapeutics | 5,586,547 | $0.52 |
| Pfizer | 5,529,726 | $40.28 |
| Codiak BioSciences | 5,360,236 | $0.23 |
| Novo Integrated Sciences | 5,034,479 | $0.13 |
| Ginkgo Bioworks | 4,764,118 | $1.24 |
| Aptinyx | 4,691,995 | $0.14 |
| Healthcare Triangle | 4,621,896 | $0.46 |
| Iovance Biotherapeutics | 4,391,700 | $6.13 |
| Clover Health | 3,753,111 | $0.83 |
| Unity Biotechnology | 3,690,580 | $2.13 |
| Ardelyx | 3,645,369 | $4.21 |
| Cidara Therapeutics | 3,431,903 | $1.03 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is installed...
CLICK TO LEARN MORE
